Edwards Lifesciences FY Conference Summary Company Overview - **Company**: Edwards Lifesciences (NYSE: EW) - **Date of Conference**: March 10, 2026 - **Key Speakers**: Scott Ullem (CFO), Mark Wilterding (Head of Investor Relations), Sydney Bailey (Investor Relations Team) Core Industry Insights - **Sustainable Growth**: Edwards Lifesciences aims for double-digit sustainable growth, driven by established TAVR business and emerging TMTT (Transcatheter Mitral and Tricuspid Therapies) [3][4] - **TAVR Business**: TAVR remains a cornerstone of growth, expected to grow mid-single digits annually [7] - **TMTT Growth**: TMTT is projected to reach $2 billion in revenue by 2030, with expected growth rates of 35%-45% in 2026 [7][8] Financial Projections - **TMTT Revenue**: Expected to grow from over $500 million in 2025 to $740 million-$780 million in 2026 [8] - **Overall Growth Expectation**: Anticipated double-digit growth of approximately 10% annually, combining TAVR, TMTT, and surgical business performance [8] Product Development and Market Strategy - **Innovative Therapies**: Introduction of new therapies like PASCAL for mitral and tricuspid, and SAPIEN M3 for mitral valve replacement, providing options for patients historically limited to surgical interventions [10][11] - **Heart Failure Management**: Development of Cordella device for heart failure management, addressing a significant patient population with limited treatment options [16][17] - **Aortic Regurgitation**: Acquisition of technology for catheter-based replacement of diseased aortic valves, with a focus on addressing different disease states [21][22] Market Opportunities - **EARLY TAVR Trial**: Results from the trial indicate the need for valve replacement in severe aortic stenosis patients regardless of symptoms, leading to increased physician interest [25][26] - **CMS Evaluation**: Anticipation of a more accommodating National Coverage Determination (NCD) to facilitate patient referrals for valve replacement [26] Long-term Vision - **Comprehensive Care**: Emphasis on developing multi-device and multi-therapy solutions for patients at risk of heart failure, recognizing the interplay between different structural heart conditions [20][21] - **Strategic Investments**: Commitment to investing in technologies that align with core competencies, particularly in structural heart failure [21] Additional Considerations - **Patient Eligibility**: Importance of a toolkit approach to cater to diverse patient anatomies and treatment needs, ensuring tailored therapeutic interventions [13] - **Market Dynamics**: Recognition of differing opinions within the medical community regarding the timing of treatment for aortic stenosis patients [28]

Core Insights - Daxor Corporation announced new data indicating that blood volume analysis (BVA) can significantly improve survival rates for hospitalized heart failure patients when performed prior to discharge [1][2] Company Overview - Daxor Corporation (Nasdaq: DXR) is a leader in blood volume measurement technology, focusing on innovation in blood volume testing [3] - The company developed the BVA-100, the only FDA-cleared diagnostic blood test for quantifying blood volume status and composition [3] - Over 65,000 tests have been conducted in leading U.S. hospitals, contributing to improved performance metrics and reduced mortality and readmissions in heart failure and critical care [3] Study Findings - A study involving 1,237 hospitalized heart failure patients showed that those identified as "euvolemic" through BVA had significantly better one-year survival rates compared to those who were hypervolemic [2][5] - The hazard ratio for death was found to be 2.61 times higher in the hypervolemic group compared to the euvolemic group, with a statistically significant p-value of 0.002 [5] - The correlation between blood volume status and survival outcomes remained significant even after adjusting for comorbidities, underscoring the clinical value of BVA [5] Implications for Heart Failure Management - The findings suggest that BVA can be a critical tool for optimizing treatment and ensuring proper decongestion before patient discharge [2] - The study supports the notion that precision volume management guided by BVA technology can save lives and improve outcomes for heart failure patients [2]